Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysozyme-like protein 2 (LYZL2) belongs to the glycoside hydrolase family 22, sharing significant structural similarity to classical c-type lysozymes but with notable functional divergence[1][6]. The protein is encoded on human chromosome 10 and is predominantly expressed in the male reproductive system, such as the testis and epididymis[3][5]. Unlike canonical lysozymes, which are potent antimicrobial enzymes found in saliva and other tissues, LYZL2 demonstrates altered or reduced catalytic activity due to amino acid substitutions in key active site residues[1][6]. Structurally, it retains the lysozyme fold and binding pockets, but evolutionary gene duplication and divergence have resulted in tissue-specific expression and putative roles in reproduction, possibly related to sperm physiology and interactions[5][1]. As of now, LYZL2 is not recognized as a clinically significant therapeutic target, nor is it the focus of any known pharmacological interventions or drug development studies[5][6]. Several aliases exist due to historical gene naming conventions and its similarity to other lysozyme paralogs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysozyme-like protein 2 (LYZL2).